Published in Clin Ophthalmol on June 01, 2008
Effects of anti-VEGF agents on rat retinal Müller glial cells. Mol Vis (2010) 0.80
Editorial foreword. Clin Ophthalmol (2008) 0.75
Quantifying the increasing use of anti-vascular endothelial growth factor therapy in ophthalmology. Mcgill J Med (2011) 0.75
Ranibizumab for neovascular age-related macular degeneration. N Engl J Med (2006) 30.63
Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med (2006) 20.84
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med (1994) 16.24
Pegaptanib for neovascular age-related macular degeneration. N Engl J Med (2004) 12.01
Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev (2004) 11.69
Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology (1992) 10.88
The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol (1991) 5.61
Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol (2003) 5.22
Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol (1984) 4.68
Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol (1993) 3.78
Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol (1996) 3.49
Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci (1996) 3.21
Retinopathy of prematurity. Angiogenesis (2007) 3.20
Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol (2003) 3.17
Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology (2007) 3.08
How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol (2003) 3.07
Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci (2005) 2.94
Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem (1994) 2.87
Clinical update: new treatments for age-related macular degeneration. Lancet (2007) 2.65
Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol (2002) 2.57
Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol (2007) 2.51
Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology (2003) 2.47
Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology (2005) 2.43
Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology (1996) 2.41
The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med (2006) 2.12
Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol (2006) 2.04
Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol (2005) 1.97
Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci (2003) 1.93
Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina (2006) 1.91
Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol (1996) 1.90
Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Arch Ophthalmol (2002) 1.71
Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology (1998) 1.68
Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Eye (Lond) (2007) 1.63
Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina (2002) 1.62
Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology (1998) 1.58
VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci (2004) 1.45
Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol (2006) 1.39
Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina (2007) 1.31
Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina (2005) 1.23
Ocular neovascularization: basic mechanisms and therapeutic advances. Surv Ophthalmol (2007) 1.23
Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology (2007) 1.12
Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology (2007) 1.12
Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor. Invest Ophthalmol Vis Sci (2000) 1.06
Serum and plasma levels of FGF-2 and VEGF in healthy blood donors. Angiogenesis (2002) 1.04
Photodynamic therapy with verteporfin (Visudyne): impact on ophthalmology and visual sciences. Invest Ophthalmol Vis Sci (2000) 1.03
A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration. Ophthalmology (2007) 1.00
Ranibizumab for neovascular age-related macular degeneration. N Engl J Med (2007) 0.94
Targeted pharmacotherapy of retinal diseases with ranibizumab. Drugs Today (Barc) (2007) 0.93
Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Ophthalmic Surg Lasers Imaging (2006) 0.92
Expression of vascular endothelial growth factor and receptor tyrosine kinases in cardiac ischemia/reperfusion injury. Cardiovasc Pathol (2007) 0.90
Remodeling after stroke. Nat Med (2006) 0.89
Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib. Retina (2007) 0.88
Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization. Am J Ophthalmol (2006) 0.84
Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK. Pharmacoeconomics (2007) 0.83
Vascular endothelial growth factor, a multifunctional polypeptide. P R Health Sci J (1996) 0.83
Value-based medicine and interventions for macular degeneration. Curr Opin Ophthalmol (2007) 0.79
Aptamers, intramers, and vascular endothelial growth factor. Int Ophthalmol Clin (2004) 0.76